Cantor Fitzgerald Decreases Earnings Estimates for Exagen

Exagen Inc. (NASDAQ:XGN - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Exagen in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($0.61) per share for the year, down from their prior forecast of ($0.59). Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 price objective on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.

A number of other equities research analysts also recently issued reports on XGN. William Blair restated an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th. UBS Group reiterated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. BTIG Research reiterated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Finally, Canaccord Genuity Group boosted their price objective on Exagen from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Exagen currently has an average rating of "Buy" and a consensus target price of $7.50.

Exagen Stock Performance

Shares of Exagen stock traded up $0.57 during trading hours on Monday, reaching $6.60. 600,762 shares of the stock traded hands, compared to its average volume of 114,676. The company has a 50 day moving average price of $5.07 and a 200 day moving average price of $4.34. The firm has a market capitalization of $140.58 million, a price-to-earnings ratio of -7.02 and a beta of 1.50. Exagen has a one year low of $1.71 and a one year high of $7.20. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). The business had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same period in the previous year, the company posted ($0.19) EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new position in Exagen in the 1st quarter worth approximately $25,000. Huntleigh Advisors Inc. lifted its holdings in Exagen by 16.8% in the 1st quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company's stock worth $298,000 after purchasing an additional 11,939 shares in the last quarter. Palumbo Wealth Management LLC lifted its holdings in Exagen by 14.4% in the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company's stock worth $356,000 after purchasing an additional 12,501 shares in the last quarter. Toronto Dominion Bank purchased a new position in Exagen in the 4th quarter worth approximately $3,655,000. Finally, Driehaus Capital Management LLC purchased a new position in Exagen in the 4th quarter worth approximately $1,716,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).